Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496253 | 0.83 | KDM4E (0.38) | TDP1L3MBTL1KDM4EPOLBHTT | |
| SCHEMBL17756845 | 0.83 | AHR (0.44) | TDP1L3MBTL1KDM4EPOLBTNF | |
| SCHEMBL25461633 | 0.80 | GRM4 (0.38) | TDP1L3MBTL1KDM4EPOLBHTT | |
| SCHEMBL27327007 | 0.79 | MAPK10 (0.47) | TDP1L3MBTL1KDM4EPOLBHTT | |
| SCHEMBL9779216 | 0.79 | TDP1 (0.63) | TDP1L3MBTL1KDM4EHTTMAPT | |
| SCHEMBL29467234 | 0.79 | TDP1 (0.63) | TDP1L3MBTL1KDM4EHTTMAPT | |
| SCHEMBL17690389 | 0.79 | KMT2A (0.42) | TDP1POLBHPGDGRM4MAPK10 | |
| SCHEMBL25493421 | 0.79 | AHR (0.49) | KDM4EHTTMAPTHPGDHSD17B10 | |
| SCHEMBL30521901 | 0.77 | KDM4E (0.46) | KDM4EPOLBHTTRAD52MAPT | |
| SCHEMBL431566 | 0.77 | KDM4E (0.46) | KDM4EPOLBHTTRAD52MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220223810-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-07-14 | — | — | US | claimed |
| US-20220223810-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-7960548-B2 | Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1883403-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | US ARMY, SECRETARY OF THE ARMY | 2007-04-05 | — | — | US | disclosed |
| WO-2006119148-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-09 | — | — | WO | disclosed |
| US-4767764-A | Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines having opioid antagonist and/or appetite-controlling properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| US-4767764-A | Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines having opioid antagonist and/or appetite-controlling properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| US-4767764-A | Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines having opioid antagonist and/or appetite-controlling properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0250855-A1 | Alkoxyalkyl and alkylmer-captoalkyl substituted bridged benzofuroisoquinolines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| EP-0250855-A1 | Alkoxyalkyl and alkylmer-captoalkyl substituted bridged benzofuroisoquinolines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| EP-0250855-A1 | Alkoxyalkyl and alkylmer-captoalkyl substituted bridged benzofuroisoquinolines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| EP-0070427-B1 | OCTAHYDRO-4A,7-ETHANO- AND -ETHENO-BENZOFURO(3,2-E)ISOQUINOLINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0164136-A1 | Octahydro-4a,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline-4one derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-11 | — | — | EP | disclosed |
| US-4477456-A | Octahydro-4A,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline derivatives having analgesic, narcotic antagonist and anorexigenic properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| US-4477456-A | Octahydro-4A,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline derivatives having analgesic, narcotic antagonist and anorexigenic properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0070427-A2 | Octahydro-4a,7-ethano- and -etheno-benzofuro(3,2-e)isoquinoline derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | FGFR1, FGFR3, MET | TDP1 3072/4885L3MBTL1 1844/4885KDM4E 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.